Skip to main content

Table 3 Mean difference in serum phosphorus compared to baseline at each visit in the maintenance period

From: Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China

Change in serum phosphorus from baseline

Lanthanum carbonate

Placebo

P value

Mean(95%CI)(Lanthanum carbonate- Placebo)

FAS

    

Day 42 – Day 0

    

No. of patients (Missing)

113(1)

113(0)

  

Mean (SD)

0.04(0.52)

0.55(0.63)

< 0.001

−0.51(−0.67, -0.36)

Day 56 – Day 0

    

No. of patients (Missing)

113(1)

113(0)

  

Mean(SD)

0.15(0.52)

0.63(0.62)

< 0.001

−0.48(−0.63, -0.33)

Hemodialysis subgroup

    

Day 42 – Day 0

    

No. of patients (Missing)

81(1)

82(0)

  

Mean(SD)

0.07(0.59)

0.53(0.71)

< 0.001

−0.46(−0.66, -0.25)

Day 56 – Day 0

    

No. of patients (Missing)

81(1)

82(0)

  

Mean(SD)

0.20(0.57)

0.62(0.68)

< 0.001

−0.42(−0.61, -0.22)

Peritoneal dialysis subgroup

    

Day 42 – Day 0

    

No. of patients (Missing)

32(0)

31(0)

  

Mean(SD)

−0.06(0.24)

0.61(0.33)

0.000

−0.67(−0.82, -0.53)

Day 56 – Day 0

    

No. of patients (Missing)

32(0)

31(0)

  

Mean(SD)

0.01(0.32)

0.65(0.42)

0.000

−0.64(−0.83, -0.46)